SACCHI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.229
EU - Europa 14.555
AS - Asia 12.928
SA - Sud America 1.705
AF - Africa 361
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 17
Totale 56.833
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.812
GB - Regno Unito 6.392
CN - Cina 3.918
SG - Singapore 3.675
IT - Italia 2.181
HK - Hong Kong 1.633
SE - Svezia 1.322
BR - Brasile 1.287
VN - Vietnam 1.287
DE - Germania 1.076
UA - Ucraina 771
FI - Finlandia 667
FR - Francia 598
RU - Federazione Russa 566
TR - Turchia 511
KR - Corea 389
BD - Bangladesh 290
IN - India 285
BG - Bulgaria 262
CA - Canada 220
AR - Argentina 146
MA - Marocco 144
ID - Indonesia 133
IQ - Iraq 112
IE - Irlanda 107
NL - Olanda 104
JP - Giappone 98
PL - Polonia 94
MX - Messico 93
ZA - Sudafrica 79
PK - Pakistan 71
ES - Italia 66
EC - Ecuador 63
CO - Colombia 61
MY - Malesia 60
AE - Emirati Arabi Uniti 54
CZ - Repubblica Ceca 51
SA - Arabia Saudita 51
PH - Filippine 49
BE - Belgio 44
CH - Svizzera 43
VE - Venezuela 37
UZ - Uzbekistan 36
AT - Austria 34
CL - Cile 34
LT - Lituania 32
AU - Australia 30
IR - Iran 30
JO - Giordania 26
TW - Taiwan 26
KE - Kenya 25
PE - Perù 25
AZ - Azerbaigian 24
RO - Romania 24
TN - Tunisia 23
IL - Israele 22
NP - Nepal 22
PY - Paraguay 21
EG - Egitto 18
CR - Costa Rica 16
JM - Giamaica 16
AL - Albania 15
TH - Thailandia 15
BH - Bahrain 14
BO - Bolivia 13
BZ - Belize 13
DZ - Algeria 13
PT - Portogallo 13
ET - Etiopia 12
EU - Europa 12
KG - Kirghizistan 12
KZ - Kazakistan 12
PA - Panama 12
UY - Uruguay 12
HU - Ungheria 11
LB - Libano 11
BY - Bielorussia 10
DO - Repubblica Dominicana 10
PS - Palestinian Territory 10
DK - Danimarca 9
NG - Nigeria 9
NO - Norvegia 9
SN - Senegal 9
GR - Grecia 8
HR - Croazia 8
NZ - Nuova Zelanda 8
CY - Cipro 7
OM - Oman 7
SY - Repubblica araba siriana 7
LV - Lettonia 6
RS - Serbia 6
AM - Armenia 5
HN - Honduras 5
LY - Libia 5
MD - Moldavia 5
NI - Nicaragua 5
QA - Qatar 5
TT - Trinidad e Tobago 5
A2 - ???statistics.table.value.countryCode.A2??? 4
EE - Estonia 4
Totale 56.742
Salva come PNG Salva come JPEG
Città #
Southend 5.360
Ashburn 2.532
Singapore 2.327
Santa Clara 2.261
Fairfield 2.102
Hong Kong 1.602
Woodbridge 1.524
Jacksonville 1.498
Chandler 1.443
Houston 1.218
Hefei 1.213
Dearborn 1.033
Ann Arbor 1.031
San Jose 875
Beijing 817
Wilmington 809
Nyköping 756
Seattle 735
Cambridge 698
London 608
Los Angeles 504
Ho Chi Minh City 411
New York 395
The Dalles 386
Seoul 378
Helsinki 377
Council Bluffs 363
Chicago 354
Modena 316
Princeton 290
Hanoi 282
Eugene 261
Milan 260
San Diego 260
Sofia 255
Izmir 251
Lauterbourg 211
Des Moines 195
Frankfurt am Main 188
Buffalo 181
Moscow 168
Dallas 167
Salt Lake City 132
Munich 122
Shanghai 118
Rome 117
São Paulo 112
Casablanca 109
Dublin 102
Columbus 99
Falls Church 86
Orem 83
Jakarta 79
Redwood City 78
Phoenix 71
San Francisco 67
Warsaw 66
Boardman 64
Montreal 63
Denver 62
Elk Grove Village 62
Bremen 60
Guangzhou 59
Atlanta 58
Da Nang 57
Norwalk 56
Tokyo 56
Brooklyn 53
Tampa 52
Toronto 52
Fremont 49
Nanjing 48
Turku 47
Rio de Janeiro 44
Haiphong 41
Baghdad 40
Brussels 39
Boston 38
Chennai 38
Kunming 37
Miami 37
Sterling 37
Miano 36
Naples 36
Belo Horizonte 34
Brno 33
Jinan 32
Falkenstein 31
Johannesburg 31
Poplar 30
Turin 30
Dhaka 29
Lancaster 29
Dong Ket 28
Mumbai 27
San Mateo 27
Kent 26
Tashkent 26
Tivoli 26
Verona 26
Totale 40.122
Salva come PNG Salva come JPEG
Nome #
Clinical activity and safety of combination immunotherapy with interferon-(2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. 1.277
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 693
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 616
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 523
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 489
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 443
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 439
Utilità clinica del dosaggio della beta-tromboglobulina e del fattore piastrinico 4 429
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 411
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 405
Cinetica piastrinica e indicazione alla splenectomia nella porpora trombocitopenica idiopatica 397
Leucemia eosinofila cronica: descrizione di un caso clinico a lunga sopravvivenza 393
Cell-penetrating CaCO3nanocrystals for improved transport of NVP-BEZ235 across membrane barrier in T-cell lymphoma 387
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 381
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 381
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 374
Activity of BKM120 and BEZ235 against lymphoma cells 369
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 368
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 363
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 362
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 362
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 347
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 340
A concise review of lenalidomide therapy for follicular lymphoma 340
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study 338
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 337
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines 336
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 335
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 333
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 322
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 321
Diagnosis of essential thrombocythemia at platele counts between 400 and 600x10(9)/L. 317
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 315
Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience 315
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 314
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 313
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 312
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 308
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 307
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 306
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 305
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 303
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 303
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 301
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 299
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 299
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 296
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 292
A PROSPECTIVE COMPARISON BETWEEN TREATMENT WITH PHLEBOTOMY ALONE AND WITH INTERFERON-ALPHA IN PATIENTS WITH POLYCYTHEMIA-VERA 290
Alpha-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Group on ET 290
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 289
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 287
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 285
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases 284
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 282
Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab (FC+R) in Relapsed Follicular Lymphoma Patients. 280
Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. 277
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 275
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 275
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 275
Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia 274
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 274
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 274
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 273
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 273
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 272
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. 271
Effects of Enzastaurin, Alone or in Combination, on Signalling Pathway Controlling Growth and Survival of B-Cell Lymphoma Cell LinesBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 4978 268
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 267
Chromosomes in paroxysmal nocturnal haemoglobinuria. 266
Epidermiological, diagnostic, therapeutic and prognostic aspects of essential thrombocithemia in a retrospective study of the GIMMC group in two thousand patients. 266
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 264
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 264
Isodicentric X chromosome in myeloproliferative disorders. 263
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 261
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 261
Extremely low frequency pulsed electromagnetic fields increase cell proliferation in lymphocytes from young and aged subjects. 260
Acute nonlymphocytic leukemia with trisomy 4. 259
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 253
The Oral PKC-ß Inhibitor Enzastaurin (LY317615) Suppress Phosphorylation and Induces Apoptosis in Multiple Myeloma Cell Lines by Inhibition of AKT Pathway. 253
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 253
Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression 252
Analysis of proliferation activity of myeloid leukaemia cell subsets in ANLL 250
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 249
Cromosomi marker ed anomalie nucleari nei linfociti di due pazienti con sindrome di Sezary/micosi fungoide. In problemi e prospettive nella medicina moderna. 248
Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes. 248
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. 247
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 246
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors 245
Alterazione della regione p22-p23 del cromosoma 6 associata a sindrome mieloproliferativa (MPS). 244
THE USE OF THE ALKALINE PHOSPHATASE-ANTIALKALINE PHOSPHATASE TECHNIQUE FOR IMMUNOPHENOTYPING ACUTE MYELOID-LEUKEMIA 244
All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi) 242
Leucemia e tricoleucociti: studio clinico patologico di 30 casi 242
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 240
Systemic sarcoidosis associated with interferon-alpha treatment for chronic myelogenous leukemia 239
Descrizione di un metodo semplificato per lo studio della cinetica piastrinica 238
Non-Hodgkin Lymphoma in Psoriatic Arthritis Treated with Sequential, Multiple Anti-TNF-α Agents: A Case Report 237
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 235
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 233
Bortezomib and plasma cell leukemia 232
Totale 31.985
Salva come PNG Salva come JPEG
Categoria #
all - tutte 194.085
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 194.085
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021234 0 0 0 0 0 0 0 0 0 0 0 234
2021/20224.305 114 538 357 443 160 285 188 264 481 280 582 613
2022/20234.224 523 480 272 401 462 745 92 390 510 41 198 110
2023/20242.701 123 154 168 209 617 214 461 275 57 47 108 268
2024/20258.470 328 86 112 616 1.717 1.195 626 412 1.010 429 785 1.154
2025/202617.325 1.064 785 1.423 1.856 2.245 1.293 1.945 923 1.661 1.673 2.241 216
Totale 57.115